Joined Crestview in July 2005 after graduating from Harvard Business School. Prior to HBS, Mr. Chu was an associate at The Carlyle Group, where he evaluated and executed transactions in the healthcare industry, including pharmaceuticals, medical devices, facility-based providers, managed care and outsourcing. Prior to joining Carlyle, Mr. Chu was an analyst in the healthcare investment banking team at Goldman Sachs, where he completed a range of M&A and financing assignments for both early stage and Fortune 500 companies. Mr. Chu is on the board of Symbion. Mr. Chu received his A.B. in Classics from Harvard College, summa cum laude, where he was elected to Phi Beta Kappa.